PE38997A1 - Antagonista de taquicinina - Google Patents

Antagonista de taquicinina

Info

Publication number
PE38997A1
PE38997A1 PE1995286859A PE28685995A PE38997A1 PE 38997 A1 PE38997 A1 PE 38997A1 PE 1995286859 A PE1995286859 A PE 1995286859A PE 28685995 A PE28685995 A PE 28685995A PE 38997 A1 PE38997 A1 PE 38997A1
Authority
PE
Peru
Prior art keywords
phenyl
compound
formula
disstituted
carbamoil
Prior art date
Application number
PE1995286859A
Other languages
English (en)
Spanish (es)
Inventor
Soo Young Ko
Christopher Walpole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9425085.9A external-priority patent/GB9425085D0/en
Priority claimed from GBGB9426016.3A external-priority patent/GB9426016D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE38997A1 publication Critical patent/PE38997A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
PE1995286859A 1994-12-13 1995-12-11 Antagonista de taquicinina PE38997A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425085.9A GB9425085D0 (en) 1994-12-13 1994-12-13 Organic compounds
GBGB9426016.3A GB9426016D0 (en) 1994-12-22 1994-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
PE38997A1 true PE38997A1 (es) 1997-10-02

Family

ID=26306161

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995286859A PE38997A1 (es) 1994-12-13 1995-12-11 Antagonista de taquicinina

Country Status (17)

Country Link
EP (1) EP0797583A1 (no)
JP (1) JPH10511935A (no)
AR (1) AR001332A1 (no)
AU (1) AU4343796A (no)
BR (1) BR9509997A (no)
CA (1) CA2204130A1 (no)
CO (1) CO4700289A1 (no)
CZ (1) CZ179097A3 (no)
FI (1) FI971685A (no)
HU (1) HUT77002A (no)
IL (1) IL116323A0 (no)
NO (1) NO972526D0 (no)
PE (1) PE38997A1 (no)
PL (1) PL320217A1 (no)
SK (1) SK74697A3 (no)
TR (1) TR199501568A2 (no)
WO (1) WO1996018643A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
ES2267153T3 (es) * 1996-10-07 2007-03-01 MERCK SHARP & DOHME LTD. Antagonistas del receptor nk-1 penetrantes del snc como agentes antidepresivos y/o antiansiedad.
WO2000048623A1 (en) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
NZ565111A (en) 2005-07-15 2011-10-28 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
WO2008084261A1 (en) 2007-01-10 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2717509A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
NZ599343A (en) 2009-10-14 2014-05-30 Merck Sharp & Dohme Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2624045C2 (ru) 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
PT2925888T (pt) 2012-11-28 2017-12-13 Merck Sharp & Dohme Composições e métodos para tratamento do cancro
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH05186498A (ja) * 1991-12-27 1993-07-27 Japan Tobacco Inc プロリン誘導体

Also Published As

Publication number Publication date
PL320217A1 (en) 1997-09-15
JPH10511935A (ja) 1998-11-17
CA2204130A1 (en) 1996-06-20
IL116323A0 (en) 1996-03-31
BR9509997A (pt) 1997-12-30
SK74697A3 (en) 1997-11-05
FI971685A (fi) 1997-08-13
TR199501568A2 (tr) 1996-07-21
CO4700289A1 (es) 1998-12-29
AU4343796A (en) 1996-07-03
HUT77002A (hu) 1998-03-02
AR001332A1 (es) 1997-10-22
CZ179097A3 (en) 1997-10-15
MX9703957A (es) 1997-09-30
EP0797583A1 (en) 1997-10-01
FI971685A0 (fi) 1997-04-18
WO1996018643A1 (en) 1996-06-20
NO972526L (no) 1997-06-03
NO972526D0 (no) 1997-06-03

Similar Documents

Publication Publication Date Title
PE38997A1 (es) Antagonista de taquicinina
PE52396A1 (es) Nuevo compuesto que puede mantener, aumentar o restaurar la sensibilidad de las celulas a los agentes terapeuticos o profilacticos
ES2059327T3 (es) Derivados de tetrahidronaftaleno y de indano, obtencion de los mismos y utilizacion en preparados farmaceuticos.
ATE89263T1 (de) Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
PT1075259E (pt) Novos analogos gordos para o tratamento de diabetes
ATE524433T1 (de) Trpv1 agonisten , zubereitungen die diese enthalten und ihre anwendung
DE69722027D1 (de) Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung
ZA842185B (en) New n-aryl-n'-cycloalkylalkanoyl-piperazine and process for the production thereof
MX9207335A (es) Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene.
PE58599A1 (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas
PE120099A1 (es) Nueva 3,4-diariltiazolina-2-ona o 2-tiona derivados, sus metodos de preparacion y su uso terapeutico
DE3583872D1 (de) Dihydropyridin-derivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zusammensetzungen, und verfahren zur herstellung dieser zusammensetzungen.
ES8301890A1 (es) Procedimiento para la preparacion de nuevas fenilalcohilaminas .
FR2713085B1 (fr) Composition tinctoriale contenant des p-phénylènediamines soufrées et procédés de teinture correspondants, nouvelles p-phénylènediamines soufrées et leur procédé de préparation.
KR910700225A (ko) 할로 치환된 아미노테트랄린
ATE178059T1 (de) 4-phenylcarbamoyl-3-isoxazolecarbonsäure-deriva e mit entzündungshemmender aktivität
DE69618050T2 (de) Substituierte Benzylthienylpiperazine, ihre Anwendung als Arzneimittel und Verfahren für ihre Herstellung
PT76335B (de) Neue basisch substituierte 4-phenyl-4,5,6,7-tetrahydro-thieno-<2,3-c>pyridine verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ES2145480T3 (es) Amidas de acido carbamoilcarboxilico.
DE69316392D1 (de) Azanoradamantane
KR930019639A (ko) 알레르기/천식치료 효과를 갖는 이미노카복실산 유도체 및 이의 제조방법
KR870003082A (ko) 옥스에탄 및 티에탄 유도체의 제조방법
KR910006292A (ko) 방향족 산의 n-아자비시클로 [3.3.0] 옥탄 아미드
ES2040744T3 (es) Un procedimiento para preparar derivados de 1,2,4-triazinona.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed